Adrenocortical Carcinoma Market Report 2026

Adrenocortical Carcinoma Market Overview

• Adrenocortical Carcinoma market size has reached to $3.76 billion in 2025 • Expected to grow to $4.62 billion in 2030 at a compound annual growth rate (CAGR) of 4.2% • Growth Driver: The Increase In Prevalence Rates Of Rare Cancer Growth On The Market • Market Trend: Innovative Therapeutic Approaches In Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Adrenocortical Carcinoma Market?

Adrenocortical carcinoma (ACC) is a rare and aggressive cancer that originates in the outer layer (cortex) of the adrenal glands. The adrenal glands are small, triangular organs on top of each kidney that produce hormones essential for regulating metabolism, immune response, blood pressure, and stress response. Adrenocortical carcinoma (ACC) can cause hormone imbalances, leading to symptoms such as weight gain, high blood pressure, or virilization (excess male traits). The main types of adrenocortical carcinoma are localized adrenocortical carcinoma and metastatic adrenocortical carcinoma. Localized adrenocortical carcinoma is a rare and aggressive cancer that originates in the adrenal glands and is confined to the adrenal gland without spreading to other parts of the body. These types are treated through various therapeutic approaches, including surgery, chemotherapy, targeted therapy, radiation therapy, and adjuvant therapy. The key end users of these treatments include hospitals and clinics, ambulatory surgical centers, and cancer research institutes.

What Is The Adrenocortical Carcinoma Market Growth Forecast?

The adrenocortical carcinoma market size is expected to see steady growth in the next few years. It will grow to $4.62 billion in 2030 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to advancements in targeted therapies, rise in minimally invasive and laparoscopic procedures, expansion of specialized cancer research institutes, increasing patient awareness and early detection, growing adoption of combination therapy protocols. Major trends in the forecast period include increasing focus on early diagnosis and screening techniques, rising adoption of minimally invasive surgical procedures, expansion of targeted and adjuvant therapies, growing awareness of hormonal imbalance symptoms, enhanced cancer research on localized and metastatic acc.

Global Adrenocortical Carcinoma Market Segmentation

1) By Type: Localized Adrenocortical Carcinoma, Metastatic Adrenocortical Carcinoma 2) By Therapy: Surgery, Laparoscopic Surgery, Open Surgery, Chemotherapy, Targeted Therapy, Radiation Therapy, External Beam Radiation Therapy, Adjuvant Therapy 3) By End User: Hospitals And Clinics, Specialized Oncology & Endocrine Cancer Centers, Academic Medical Centers Subsegments: 1) By Localized Adrenocortical Carcinoma: Early-Stage Localized Adrenocortical Carcinoma, Advanced Localized Adrenocortical Carcinoma 2) By Metastatic Adrenocortical Carcinoma: Metastasis To Distant Organs, Local Regional Metastasis

What Is The Driver Of The Adrenocortical Carcinoma Market?

The increase in prevalence rates of rare cancers is expected to propel the growth of the adrenocortical carcinoma market going forward. Rare cancers are referred to as distinguished by low incidence rates and a significant influence on patient outcomes, needing specialist techniques for diagnosis and therapy. The increase in prevalence rates of rare cancers is driven by several factors, such as developments in diagnostic methods that have enhanced the detection of adrenocortical carcinoma, enabling the early identification of instances that could have gone undetected in the past. Adrenocortical carcinoma (ACC) contributes to the increase in prevalence rates of rare cancers by being a relatively uncommon yet aggressive cancer type, highlighting the need for improved diagnosis and treatment strategies. For instance, in February 2024, according to a report by the International Agency for Research on Cancer of the World Health Organization, a Switzerland-based intergovernmental organization, rare cancers are defined as cancer types with fewer than 6 new cases per 100,000 people annually. Collectively, rare cancers make up approximately 25% of all cancer diagnoses. Therefore, the increase in prevalence rates of rare cancers will drive the growth of the adrenocortical carcinoma industry.

Key Players In The Global Adrenocortical Carcinoma Market

Major companies operating in the adrenocortical carcinoma market are HRA Pharma S.A., Servier Laboratories, Roche Holding AG, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, Sanofi S.A., Ipsen S.A., Exelixis Inc., Tempest Therapeutics Inc., Orphagen Pharmaceuticals Inc., Millendo Therapeutics Inc., Pfizer Inc, Novartis AG, Bayer AG, Takeda Pharmaceutical Company, Astellas Pharma Inc., Johnson & Johnson, Gilead Sciences

Global Adrenocortical Carcinoma Market Trends and Insights

Major companies operating in the adrenocortical carcinoma market are focusing on developing innovative therapies, such as small-molecule drugs, to target specific tumor pathways and improve patient outcomes. A small-molecule drug is a low molecular weight compound that penetrates cells to target proteins or enzymes, regulating biological processes and treating diseases such as adrenocortical carcinoma by inhibiting tumor growth pathways. For instance, in January 2023, Orphagen Pharmaceuticals, Inc., a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had granted Rare Pediatric Disease Designation (RPDD) for its investigational drug OR-449, aimed at treating pediatric adrenocortical carcinoma (ACC). This drug aims to treat pediatric ACC, a rare and aggressive cancer primarily affecting children. The disease often presents with symptoms linked to hormonal overproduction, such as virilization and Cushing syndrome. Diagnosis involves imaging and hormonal assessments, with prognosis influenced by factors such as age at diagnosis and tumor resectability.

What Are Latest Mergers And Acquisitions In The Adrenocortical Carcinoma Market?

In October 2024, Esteve Pharmaceuticals, S.A., a Spain-based pharmaceutical company, acquired HRA Pharma Rare Diseases from Perrigo Company plc for an undisclosed amount. With this acquisition, Esteve Pharmaceuticals aims to expand its portfolio of treatments for rare diseases, accelerate international growth, enhance patient care, and increase market reach. HRA Pharma Rare Diseases is a France-based pharmaceutical company specializing in treating rare diseases, including adrenocortical carcinoma.

Regional Outlook

North America was the largest region in the adrenocortical carcinoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Adrenocortical Carcinoma Market?

The adrenocortical carcinoma market consists of revenues earned by entities by providing services such as diagnostic services, medical treatments, patient management services, clinical trials, and research. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Adrenocortical Carcinoma Market Report 2026?

The adrenocortical carcinoma market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the adrenocortical carcinoma industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.